Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01323634 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 519
- Enrollment target
NCT01323634 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 519 participants.
The verdict
NCT01323634, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 519 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with COPD.
Interventions
- DRUG Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg
- DRUG Fluticasone Propionate 250mcg/ salmeterol 50mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 519 participants |
| Start Date | 2011-03-18 |
| Est. Completion | 2011-12-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01323634
The ClinicalTrials.gov registry entry for NCT01323634 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 519 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg is the first listed.
NCT01323634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01323634 about?
NCT01323634 is a clinical study titled "Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease". The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with COPD.
What is the current status of trial NCT01323634?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 519 participants. The study started on 2011-03-18. Estimated completion is 2011-12-14.
What interventions are being tested in trial NCT01323634?
The interventions under investigation include: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg (DRUG), Fluticasone Propionate 250mcg/ salmeterol 50mcg (DRUG).
Who is sponsoring clinical trial NCT01323634?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.